Keep Current with the Latest in Cell Biology Research

Noxopharm’s Veyonda to Begin First-Line Sarcoma Treatment Testing

Noxopharm Limited announced its CEP-2 study will begin shortly. CEP-2 is related to the Investigational New Drug approval of Veyonda® by the FDA based on evidence that Veyonda may increase generally poor response rates of sarcoma cancers to chemotherapy in combination with common chemotherapy drug, doxorubicin, for patients with soft tissue sarcomas.
[Noxopharm Limited]
Press Release
Bookmark

No account yet? Register

0
Share

Symmetry Breaking of Tissue Mechanics in Wound Induced Hair Follicle Regeneration of Laboratory and Spiny Mice

Scientists demonstrated that tissue mechanics, or the stiffness of the wound bed, the ECM, and the stiffness of the cells also partook during wound-induced hair neogenesis; the hair primordia formation was not exclusive to molecular signaling events.
[Nature Communications]
Full Article
Bookmark

No account yet? Register

0
Share

Adipocyte-Like Signature in Ovarian Cancer Minimal Residual Disease Identifies Metabolic Vulnerabilities of Tumor Initiating Cells

Investigators performed dense multi-region transcriptomics analysis of paired biopsies from 17 ovarian cancer patients before and after chemotherapy.
[JCI Insight]
AbstractFull Article
Bookmark

No account yet? Register

0
Share

An RFC4/Notch1 Signaling Feedback Loop Promotes NSCLC Metastasis and Stemness

To understand how Notch signaling was overactivated to couple tumor metastasis and self-renewal in NSCLC cells, researchers showed that RFC4, directly bound to the Notch1 intracellular domain (NICD1) to competitively abrogate CDK8/FBXW7-mediated degradation of NICD1.
[Nature Communications]
Full Article
Bookmark

No account yet? Register

0
Share

Mucosal Ribosomal Stress-Induced PRDM1 Promotes Chemoresistance via Stemness Regulation

Stress-driven ribosomal dysfunction enhanced PR domain zinc finger protein 1 (PRDM1) levels in intestinal cancer cells, which contributed to their survival and enhanced cancer cell stemness against cancer treatment.
[Communications Biology]
Full Article
Bookmark

No account yet? Register

0
Share

Functional Inhibition of Cancer Stemness-Related Protein DPP4 Rescues Tyrosine Kinase Inhibitor Resistance in Renal Cell Carcinoma

The authors established patient-derived renal cell carcinoma spheroids and showed that dipeptidyl peptidase IV (DPP4) expression was associated with stemness-related gene expression.
[Oncogene]
Abstract
Bookmark

No account yet? Register

0
Share

WPD Pharmaceuticals to Receive $6.7 Million Grant for Development of Annamycin Drug Candidate

WPD Pharmaceuticals, Inc. announced that it has been conditionally awarded a grant of $6,730,036 from the Polish National Center for Research and Development, for the development of Annamycin, the company’s drug candidate used in the treatment of Acute Myeloid Leukemia.
[WPD Pharmaceuticals, Inc.]
Press Release
Bookmark

No account yet? Register

0
Share

The Role of the p90 Ribosomal S6 Kinase Family in Prostate Cancer Progression and Therapy Resistance

Scientists review the roles of the p90 ribosomal S6 kinases in proliferation and motility, cell cycle control and therapy resistance in prostate cancer, highlighting the possible interplay between RSKs and Androgen Receptor in mediating disease progression.
[Oncogene]
Full Article
Bookmark

No account yet? Register

0
Share

Cryopreservation of Human Cancers Conserves Tumor Heterogeneity for Single-Cell Multi-Omics Analysis

Using the Chromium 10X platform, scientists sequenced a total of ~ 120,000 cells from fresh and cryopreserved replicates across three primary breast cancers, two primary prostate cancers and a cutaneous melanoma.
[Genome Medicine]
Full Article
Bookmark

No account yet? Register

0
Share

Removal of CD276+ Cells from Haploidentical Memory T-Cell Grafts Significantly Lowers the Risk of GVHD

Analysis of CD45RA-depleted haploidentical mixed lymphocytes culture revealed insufficient suppression of alloresponses in the CD4+ compartment and identified CD276 as a marker for alloreactive memory Th1 T cells.
[Bone Marrow Transplantation]
Hashimoto, H., Kasteleiner, P., Kressin, J., Müller, F., Bühring, H.-J., Handgretinger, R., & Schilbach, K. (2021). Removal of CD276 + cells from haploidentical memory T-cell grafts significantly lowers the risk of GVHD. Bone Marrow Transplantation, 1–19. https://doi.org/10.1038/s41409-021-01307-9 Cite
Full Article
Bookmark

No account yet? Register

0
Share

Engineered Red Blood Cells as an Off-the-Shelf Allogeneic Anti-Tumor Therapeutic

Researchers engineered red blood cells into artificial antigen-presenting cells presenting a peptide bound to the major histocompatibility complex I, the costimulatory ligand 4-1BBL, and interleukin-12.
[Nature Communications]
Zhang, X., Luo, M., Dastagir, S. R., Nixon, M., Khamhoung, A., Schmidt, A., Lee, A., Subbiah, N., McLaughlin, D. C., Moore, C. L., Gribble, M., Bayhi, N., Amin, V., Pepi, R., Pawar, S., Lyford, T. J., Soman, V., Mellen, J., Carpenter, C. L., … Chen, T. F. (2021). Engineered red blood cells as an off-the-shelf allogeneic anti-tumor therapeutic. Nature Communications, 12(1), 2637. https://doi.org/10.1038/s41467-021-22898-3 Cite
Full Article
Bookmark

No account yet? Register

0
Share
Share